The following is management's discussion and analysis ("MD&A") of certainsignificant factors that have affected our financial position and operatingresults during the periods included in the accompanying financial statements, aswell as information relating to the plans of our current management. This reportincludes forward-looking statements. Generally, the words "believes,""anticipates," "may," "will," "should," "expect," "intend," "estimate,""continue," and similar expressions or the negative thereof or comparableterminology are intended to identify forward-looking statements. Such statementsare subject to certain risks and uncertainties, including the matters set forthin this report or other reports or documents we file with the Securities andExchange Commission from time to time, which could cause actual results oroutcomes to differ materially from those projected. Undue reliance should not beplaced on these forward-looking statements which speak only as of the datehereof. We undertake no obligation to update these forward-looking statements.

The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto and other financial information contained elsewhere in this Form 10-K

Our Ability To Continue as a Going Concern

--------------------------------------------------------------------------------

Index

Biotechnology Product Candidates

GENERAL AMERICAN CAPITAL PARTNERS

--------------------------------------------------------------------------------

Index

Results of Operations Overview

Comparison of Years Ended December 31, 2021 and December 31, 2020

Cost of sales consists of the costs associated with the production of MyoCath and test kits, product costs, labor for production and training and lab and banking costs consistent with products and services provided.

Cost of sales was $52,030 in the year ended December 31, 2021 compared to $64,117 in the year ended December 31, 2020. The decrease is due to the decrease in revenues.

Research and development expenses were $0 in 2021 remaining the same as $0 in 2020.

Selling, General and Administrative

Gain (loss) on settlement of debt

--------------------------------------------------------------------------------

In valuing our common stock, our Board of Directors considered a number of factors, including, but not limited to:

--------------------------------------------------------------------------------

Index

Options outstanding at December 31, 2021 110,643,884 $ 0.0247

Options exercisable at December 31, 2021 93,491,384 $ 0.0256

Available for grant at December 31, 2021 34,168,070

Average Number Weighted Average

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Index

Our primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking.

Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied.

Research and Development Costs

--------------------------------------------------------------------------------

Depreciation is computed using the straight-line method over the assets' expected useful lives or the term of the lease, for assets under capital leases.

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

We allocate the proceeds received from equity financing and the attached options and warrants issued, based on their relative fair values, at the time of issuance. The amount allocated to the options and warrants is recorded as additional paid in capital.

Selling, General and Administrative

Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

Liquidity and Capital Resources

In 2021, we continued to finance our operational cash needs with cash generated from financing activities.

Economic Injury Disaster Loan (EIDL)

--------------------------------------------------------------------------------

Net cash provided by investing activities was $0 for the year ended December 31, 2021.

Existing Capital Resources and Future Capital Requirements

As of December 31, 2021, we had $8,016,314 in outstanding debt, net of debt discount of $273,216.

Off-Balance Sheet Arrangements

Recent Accounting Pronouncements

Refer to Note 1. Organization and Summary of Significant Accounting Policies in the notes to our financial statements for a discussion of recent accounting pronouncements.

Edgar Online, source Glimpses

Follow this link:
U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com